Document Detail

Reversible fetal renal failure after maternal treatment with Candesartan: a case report.
MedLine Citation:
PMID:  20132879     Owner:  NLM     Status:  MEDLINE    
Despite data suggesting that angiotensin-receptor blockers (ARBs) are associated with increased risk to the fetus, there has been an increasing exposure of ARBs in pregnancy. We report a case report regarding a woman, who accidentally was treated with Candesartan during the first 22 weeks of pregnancy. At 22 weeks of gestation the fetal kidneys were oedematous with very little amniotic fluid. The prognosis for the fetus was considered poor. Five weeks after discontinuation of Candesartan normal quantities of amnionic fluid and a visible fetal bladder was registered. After delivery at week 31, creatinine clearance, diuresis and urine examination of the neonate were within normal limits. Ultrasound examinations of the kidneys showed bilaterally marked calices, small cysts and parenchymal increased echogenety at 1 week with complete sonographic normalization at 6 weeks. However, experimental studies raise the question of potential long-term adverse effects, including renal dysfunction and arterial hypertension in adulthood.
Peter Scott Munk; Philip von Brandis; Alf Inge Larsen
Related Documents :
9061759 - In utero infection with treponema pallidum in early pregnancy.
1415739 - Fetal-maternal fluid and electrolyte relations during chronic fetal urine loss in sheep.
19683759 - Is cystatin c a promising parameter to determine postnatal outcome of prenatally diagno...
15824499 - Detection of viral deoxyribonucleic acid in amniotic fluid: association with fetal malf...
48439 - Alpha fetoprotein levels in maternal serum and in amniotic fluid from early normal preg...
9686819 - Late-onset holocarboxylase synthetase-deficiency: pre- and post-natal diagnosis and eva...
10629019 - Detrimental effect of the combination of r164s with g238s in tem-1 beta-lactamase on th...
14563089 - Induction of labor with vaginal prostaglandin e2.
9053409 - Study of side-effects of cu-t as intra-uterine contraceptive device in post medical ter...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-02-02
Journal Detail:
Title:  Reproductive toxicology (Elmsford, N.Y.)     Volume:  29     ISSN:  1873-1708     ISO Abbreviation:  Reprod. Toxicol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-04-16     Completed Date:  2010-07-13     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8803591     Medline TA:  Reprod Toxicol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  381-2     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amniotic Fluid
Antihypertensive Agents / adverse effects*
Benzimidazoles / adverse effects*
Fetus / physiopathology
Hypertension / chemically induced
Infant, Newborn
Kidney / physiopathology
Renal Insufficiency / chemically induced*,  physiopathology
Tetrazoles / adverse effects*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Benzimidazoles; 0/Tetrazoles; 60-27-5/Creatinine; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Health outcomes of children born to cosmetologists compared to children of women in other occupation...
Next Document:  Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model.